Our top pick for
BeyondSpring Inc is a biotechnology business based in the US. BeyondSpring shares (BYSI) are listed on the NASDAQ and all prices are listed in US Dollars. BeyondSpring employs 61 staff and has a market cap (total outstanding shares value) of USD$432.5 million.
|Latest market close||USD$11.78|
|52-week range||USD$9.38 - USD$18.83|
|50-day moving average||USD$12.1112|
|200-day moving average||USD$13.4665|
|Wall St. target price||USD$35.5|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.898|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-08)||-6.66%|
|1 month (2020-12-16)||4.06%|
|3 months (2020-10-15)||-21.47%|
|6 months (2020-07-15)||-18.76%|
|1 year (2020-01-15)||-35.38%|
|2 years (2019-01-15)||-37.34%|
|3 years (2018-01-12)||25.74|
|5 years (2016-01-12)||N/A|
|Gross profit TTM||USD$0|
|Return on assets TTM||-103.49%|
|Return on equity TTM||-267.71%|
|Market capitalisation||USD$432.5 million|
TTM: trailing 12 months
There are currently 923,876 BeyondSpring shares held short by investors – that's known as BeyondSpring's "short interest". This figure is 24.2% down from 1.2 million last month.
There are a few different ways that this level of interest in shorting BeyondSpring shares can be evaluated.
BeyondSpring's "short interest ratio" (SIR) is the quantity of BeyondSpring shares currently shorted divided by the average quantity of BeyondSpring shares traded daily (recently around 896966.99029126). BeyondSpring's SIR currently stands at 1.03. In other words for every 100,000 BeyondSpring shares traded daily on the market, roughly 1030 shares are currently held short.
However BeyondSpring's short interest can also be evaluated against the total number of BeyondSpring shares, or, against the total number of tradable BeyondSpring shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case BeyondSpring's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 BeyondSpring shares in existence, roughly 20 shares are currently held short) or 0.0334% of the tradable shares (for every 100,000 tradable BeyondSpring shares, roughly 33 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against BeyondSpring.
Find out more about how you can short BeyondSpring stock.
We're not expecting BeyondSpring to pay a dividend over the next 12 months.
Over the last 12 months, BeyondSpring's shares have ranged in value from as little as $9.38 up to $18.83. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BeyondSpring's is 0.5803. This would suggest that BeyondSpring's shares are less volatile than average (for this exchange).
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development and commercialization of immuno-oncology cancer therapies. The company's lead asset is the Plinabulin that is in late stage clinical trials as an anti-cancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC) for the prevention of high and intermediate risk chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a programmed cell death protein 1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody to treat small cell lung cancer; and death protein 1 or programmed death-ligand 1, an antibodies and radiation or chemotherapy for the treatment of multiple cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform using ubiquitin mediated protein degradation pathway. BeyondSpring Inc. has collaboration agreements with the Fred Hutchinson Cancer Research Center and the University of Washington. The company was founded in 2010 and is headquartered in New York, New York.
Everything we know about the Vacasa IPO, plus information on how to buy in.
Everything we know about the William Penn Bancorp IPO, plus information on how to buy in.
Everything we know about the Landos Biopharma Inc IPO, plus information on how to buy in.
Everything we know about the First High-School Education Group Co Ltd IPO, plus information on how to buy in.
Everything we know about the Knowlton Development Corp IPO, plus information on how to buy in.
Steps to owning and managing SASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SAIL, with 24-hour and historical pricing before you buy.
Steps to owning and managing SAF, with 24-hour and historical pricing before you buy.
Steps to owning and managing RDHL, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBFG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.